secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001372514-26-000048
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Q1 cash $13.9M, $5.0M equity raise post-quarter; KIO-301 enrollment nearly 50% in Phase 2
--------------------------------------------------------------------------------

- Q1 cash $13.9M; post-quarter raised $5.0M in equity from Perceptive Advisors; operational runway into late 2028.
- Phase 2 ABACUS-2 enrollment for KIO-301 nearly 50% completed; trial sites expanding due to strong patient demand.
- ABACUS-1 results published in Nature Medicine, validating KIO-301 photoswitch technology for vision restoration.
- Phase 2 KLARITY study of KIO-104 progressing; safety review upcoming to enable dose escalation.
- R&D expenses $2.1M with $1.2M Théa reimbursement; G&A $1.6M; collaboration receivables $1.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/0001372514-26-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/kprx-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer